Bank of Montreal Can reduced its holdings in Bausch Health Companies Inc. (NYSE:BHC – Get Rating) by 23.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,451,846 shares of the company’s stock after selling 766,999 shares during the period. Bank of Montreal Can owned about 0.68% of Bausch Health Companies worth $21,675,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the business. Fiera Capital Corp grew its holdings in Bausch Health Companies by 12.9% in the second quarter. Fiera Capital Corp now owns 3,445,746 shares of the company’s stock valued at $28,807,000 after purchasing an additional 393,903 shares during the period. Mackenzie Financial Corp grew its holdings in Bausch Health Companies by 81.6% in the second quarter. Mackenzie Financial Corp now owns 737,449 shares of the company’s stock valued at $6,165,000 after purchasing an additional 331,349 shares during the period. WINTON GROUP Ltd acquired a new stake in Bausch Health Companies in the second quarter valued at approximately $265,000. Blackhawk Capital Partners LLC. acquired a new stake in Bausch Health Companies in the second quarter valued at approximately $725,000. Finally, Fountainhead AM LLC boosted its stake in shares of Bausch Health Companies by 25.0% in the second quarter. Fountainhead AM LLC now owns 262,501 shares of the company’s stock worth $2,195,000 after acquiring an additional 52,417 shares during the last quarter. 70.07% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
BHC has been the subject of several research reports. Piper Sandler dropped their price target on Bausch Health Companies from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Friday, September 9th. Royal Bank of Canada boosted their price target on Bausch Health Companies from $4.50 to $8.00 and gave the stock a “sector perform” rating in a research report on Thursday, September 1st. Truist Financial cut Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. StockNews.com initiated coverage on Bausch Health Companies in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Finally, JPMorgan Chase & Co. lowered Bausch Health Companies from an “overweight” rating to a “neutral” rating in a research note on Thursday, July 28th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, Bausch Health Companies currently has an average rating of “Hold” and an average target price of $10.60.
Bausch Health Companies Stock Performance
Bausch Health Companies Profile
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.